Research Topics
| M G HudgensSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncationM G Hudgens
Department of Biostatistics, Emory University, Atlanta, Georgia 30322, USA
Biometrics 57:74-80. 2001..The methods are then applied to data from a cohort of injecting drug users in Thailand susceptible to infection from HIV-1 subtypes B and E...- Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, ThailandMichael G Hudgens
Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 98109, USA
Am J Epidemiol 155:159-68. 2002..Since many epidemiologic, virologic, and host factors can influence HIV transmission, it was difficult to conclude whether these differences in transmission probabilities were due to biologic properties associated with subtype... - Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trialsMichael G Hudgens
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, MW 500, P O Box 19024, Seattle, WA 98109, USA
Stat Med 22:463-79. 2003.... - Discrete-time semi-Markov modeling of human papillomavirus persistenceC E Mitchell
Department of Biostatistics, The University of North Carolina, Chapel Hill, NC 27599, USA
Stat Med 30:2160-70. 2011..Simulation study results are presented indicating that the semi-Markov estimator is more accurate than an estimator currently used in the HPV literature. The methods are illustrated using data from the HIV Epidemiology Research Study... - What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trialsPeter B Gilbert
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
J Infect Dis 188:179-93. 2003..The assessment suggests that a vaccine demonstrating moderately durable effects to delay therapy and to ameliorate viremia merits consideration for licensure... - Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variableMichael G Hudgens
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Biometrics 63:372-80. 2007..Theoretical and empirical evidence are presented indicating the NPMLE and MIDMLE are inconsistent. Conversely, the CMLE is shown to be consistent in general and thus is preferred... - Comparison of group testing algorithms for case identification in the presence of test errorHae Young Kim
Department of Biostatistics, School of Public Health, University of North Carolina at Chapel Hill, 3107 E McGavran Greenberg Hall, Chapel Hill, North Carolina 27599, USA
Biometrics 63:1152-63. 2007..The methodology is illustrated by comparing different pooling algorithms for the detection of individuals recently infected with HIV in North Carolina and Malawi... - HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challengesDennis Ellenberger
Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Mail Stop G 19, 1600 Clifton Road, Atlanta, GA 30333, USA
Virology 352:216-25. 2006..Therefore, improved non-human primate models for vaccine efficacy can provide novel insight and perhaps renew expectations for positive outcomes of human HIV clinical trials... - Statistical evaluation of HIV vaccines in early clinical trialsZoe Moodie
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Reasearch Center, 1100 Fairview Ave N, LE 400, PO Box 19024, Seattle, WA 98109 1024, USA
Contemp Clin Trials 27:147-60. 2006..The goal of these early trials is to narrow the number of candidate vaccines to the most promising candidates worthy of further study in efficacy trials... - Participant retention in clinical trials of candidate HIV vaccinesGuy de Bruyn
HIV Vaccine Trials Network Core Operations, Seattle, WA, USA
J Acquir Immune Defic Syndr 39:499-501. 2005..To determine predictors of loss to follow-up (LTFU) in trials of candidate HIV vaccines... - Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002Gaston Djomand
HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Public Health Rep 120:543-8. 2005..S. conducted by National Institute of Allergy and Infectious Diseases (NIAID)-funded networks from 1988 to 2002... - Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trialPeter B Gilbert
Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 191:666-77. 2005..Although the data cannot definitively discriminate between these 2 explanations, (ii) appears to be more likely... - Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trialsMichael G Hudgens
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, NW 500, PO Box 19024, Seattle 98109 1024, USA
J Immunol Methods 288:19-34. 2004..Moreover, the proposed methods have potential utility in related HIV immunopathogenesis studies and in non-HIV clinical vaccine trials... - On the analysis of viral load endpoints in HIV vaccine trialsMichael G Hudgens
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, MW 500, P O Box 19024, Seattle, WA 98109, USA
Stat Med 22:2281-98. 2003..Finite sample properties of these tests are evaluated using computer simulations... - Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trialsPeter B Gilbert
Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington 98109, USA
Biometrics 59:531-41. 2003..We show how the procedures can be used for a sensitivity analysis that quantifies how the causal effect of vaccination varies with the presumed magnitude of selection bias... - Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification testsDaniel J Westreich
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
J Clin Microbiol 46:1785-92. 2008..Used selectively and carefully, the simple models developed here can guide the selection of a pooling algorithm for the detection of AHI cases in a wide variety of settings... - Highly efficient HIV transmission to young women in South AfricaAudrey E Pettifor
Division of Infectious Diseases, School of Medicine, Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA
AIDS 21:861-5. 2007..Such findings have led to hypotheses that the probability of HIV transmission from men to women must be far higher than previously appreciated... - Estimating population size with two- and three-stage sampling designsJacqueline E Tate
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Am J Epidemiol 165:1314-20. 2007.... - Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challengesShambavi Subbarao
Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, National Center for Infectious Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
J Infect Dis 194:904-11. 2006..These data demonstrate that treatment with oral TDF provided partial protection against SHIV infection but ultimately did not protect all TDF treated animals against multiple virus challenges... - Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunityNina D Russell
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
J Infect Dis 187:226-42. 2003..When responses in natural infection were compared with vaccine-induced responses, vaccine recipient responses were > or =1 log lower, which confirms the importance of using this sensitive assay as an initial screen in vaccine protocols...